PhRMA Statement on the FDA Approving Biosimilars

Washington, D.C. (Nov. 3, 2010) – Pharmaceutical Research and Manufacturers of America (PhRMA) Associate Vice President for Scientific & Regulatory Affairs Marie A. Vodicka testified today at the Food and Drug Administration’s public hearing on federal implementation of the new biosimilars approval pathway.

PhRMA Statement Regarding Puerto Rico Law 154

Washington, D.C. (October 25, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President John Castellani [bio] released the following statement about Law 154, which was signed today in Puerto Rico:

PhRMA Urges Support for International Standards in Russian Medicines Law

Washington, D.C. (March 4, 2010) — As Russia embarks on legislative reforms to strengthen pharmaceutical regulation, the Pharmaceutical Research and Manufacturers of America’s (PhRMA) President of International Affairs Christopher A. Singer called on the Russian government to use the opportunity to align with international standards and obligations on clinical trial regulation and intellectual property rights.

The U.S. Prescription Drug Lifecycle

Innovator pharmaceutical companies produce medical advances through pioneering scientific work and large-scale investments which lead to new medicines and, over time, to generic copies that consumers use at low cost for many years.

PhRMA Statement on Senate Health Care Reform Bill

Washington, D.C. (November 19, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson released the following statement about the Senate health care reform bill:

“While we are still reviewing the Senate bill, we remain committed to do our part to make comprehensive health care reform a reality this year. We believe that all Americans should have access to high-quality, affordable health care coverage and services. If done in a smart way, health care reform will benefit patients, the economy and the future of America.

Global Partnerships

PhRMA Statement on House Passage of Health Care Reform Bill

Washington, D.C. (November 7, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson released the following statement regarding the House health care reform bill:

Comprehensive Health Care Reform Should Be National Priority

Washington, D.C. (September 9, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) President & CEO Billy Tauzin issued the following statement after President Obama’s address to a joint session of Congress on health care reform:

PhRMA Statement on Commitment to Health Care Reform

Washington, D.C. (August 18, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson today reiterated PhRMA’s commitment to health care reform:

“We have been working diligently for more than a year to advance bipartisan health care reform. We’re proud of those efforts, and they are completely consistent with our core principals, reflecting a fundamental belief that every single American should have access to high-quality, affordable health care coverage and services.

PhRMA Statement on Industry Support of Medical Education

Washington, D.C. (July 29, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement regarding industry support of continuing professional medical education:

“Because medicine constantly changes – new medicines enter the market, existing therapies are approved for additional indications and warnings are updated on labels – it is crucial for physicians to obtain information that enhances their knowledge and skills, and improves clinical outcomes.

Pages

Subscribe to RSS - Access